VYNE Therapeutics Inc. (VYNE)
1.73
0.05 (2.98%)
At close: Mar 21, 2025, 3:59 PM
2.98% (1D)
| Bid | 1.62 |
| Market Cap | 26.31M |
| Revenue (ttm) | 178.93K |
| Net Income (ttm) | -14.22M |
| EPS (ttm) | -0.93 |
| PE Ratio (ttm) | -1.86 |
| Forward PE | -3.05 |
| Analyst | Buy |
| Ask | 1.82 |
| Volume | 816,747 |
| Avg. Volume (20D) | 106,640 |
| Open | 1.63 |
| Previous Close | 1.68 |
| Day's Range | 1.63 - 1.81 |
| 52-Week Range | 1.57 - 4.30 |
| Beta | 1.25 |
About VYNE
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is als...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 25, 2018
Employees 13
Stock Exchange NASDAQ
Ticker Symbol VYNE
Website https://www.vynetherapeutics.com
Analyst Forecast
According to 2 analyst ratings, the average rating for VYNE stock is "Buy." The 12-month stock price forecast is $6.88, which is an increase of 297.69% from the latest price.
Stock Forecasts